SARS-CoV-2?Spike RBD Neutralizing?Antibody, monoclonal

Contact us
ProSci
Product Code: PSI-11-590
Product Group: Primary Antibodies
Supplier: ProSci
CodeSizePrice
PSI-11-590-0.1mg0.1mg£765.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Antibody Isotype: Human IgG1/kappa
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Western Blot (WB)
Shipping:
blue ice or RT
Storage:
For long term storage, the product should be stored at lyophilized state at -20˚C or lower..Please avoid repeated freeze-thaw cycles.This product is stable after storage at:.-20 to -70˚C for 12 months in lyophilized state from date of receipt;.-70˚C for 3 months under sterile conditions after reconstitution.

Images

1 / 7
Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
2 / 7
3 / 7
Immobilized SARS-CoV-2 S1 protein, His Tag at 2 ug/mL (100 uL/well) can bind Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 with a linear range of 0.2-1.95 ng/mL (QC tested).
4 / 7
Serial dilutions of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 was detected by Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Assay Kit with a half maximal inhibitory concentration (IC50) of 0.6265 ug/mL (Routinely tested)
5 / 7
Serial dilutions of Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody was incubated with SARS-CoV-2 pseudotyped virus at 37C for 1 hour. Afterward, Huh-7 cells were added, followed by incubation at 37C for 24h. Chemiluminescence detection was performed and the virus neutralization titers (IC50) is 2.181 nM using the Reed-Muench method.
6 / 7
FACS analysis shows that the binding of SARS-CoV-2 S protein RBD, Mouse IgG2a Fc Tag to Vero E6 cells surface ACE2 was inhibited by increasing concentration of Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1. The concentration of SARS-CoV-2 S protein RBD used is 5ug/ml. The IC50 is 10.33 ug/ml (Routinely tested)
7 / 7
FACS analysis shows that the binding of SARS-CoV-2 S1 protein, Mouse IgG2a Fc Tag to Vero E6 cells surface ACE2 was inhibited by increasing concentration of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1. The concentration of SARS-CoV-2 S1 protein used is 3ug/ml. The IC50 is 1.352 ug/ml (Routinely tested).
❮❯

Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized SARS-CoV-2 S1 protein, His Tag at 2 ug/mL (100 uL/well) can bind Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 with a linear range of 0.2-1.95 ng/mL (QC tested).
Serial dilutions of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 was detected by Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Assay Kit with a half maximal inhibitory concentration (IC50) of 0.6265 ug/mL (Routinely tested)
Serial dilutions of Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody was incubated with SARS-CoV-2 pseudotyped virus at 37C for 1 hour. Afterward, Huh-7 cells were added, followed by incubation at 37C for 24h. Chemiluminescence detection was performed and the virus neutralization titers (IC50) is 2.181 nM using the Reed-Muench method.
FACS analysis shows that the binding of SARS-CoV-2 S protein RBD, Mouse IgG2a Fc Tag to Vero E6 cells surface ACE2 was inhibited by increasing concentration of Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1. The concentration of SARS-CoV-2 S protein RBD used is 5ug/ml. The IC50 is 10.33 ug/ml (Routinely tested)
FACS analysis shows that the binding of SARS-CoV-2 S1 protein, Mouse IgG2a Fc Tag to Vero E6 cells surface ACE2 was inhibited by increasing concentration of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1. The concentration of SARS-CoV-2 S1 protein used is 3ug/ml. The IC50 is 1.352 ug/ml (Routinely tested).

Documents

Further Information

Additional Names:
spike glycoprotein
Background:
It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
Buffer:
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 . Normally trehalose is added as protectant before lyophilization.
Concentration:
batch dependent
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 ug/mL using SARS-CoV-2 Inhibitor Screening Kit .Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.
NCBI Gene ID #:
43740568
NCBI Official Name:
Surface glycoprotein
NCBI Official Symbol:
S
NCBI Organism:
SARS-CoV-2
Physical State:
Lyophilized
Purification:
>95% as determined by SDS-PAGE.
Research Area:
Infectious Disease, COVID-19
SPECIFICITY:
This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. No cross-reactivity is detected with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.
Swissprot #:
P0DTC2
User NOte:
Optimal dilutions for each application to be determined by the researcher.